14
Nov
2018

From Nova Scotia to the Forefront of Bio & Tech Investing: Julie Sunderland of Biomatics on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Raising the Bar for Sickle Cell Patients: Ted Love and Alan Anderson on The Long Run
RNA Medicines to Treat Muscle Diseases: Sarah Boyce on The Long Run
Biologic Drug Discovery With AI: Sean McClain on The Long Run
A Long-Lasting Drug Against Flu: Jeff Stein on The Long Run